Post by VectorY

An important day for #VectorY and for the ALS community. We are proud to announce that have received authorization and approval from both the UK’s MHRA and Europe’s EMA to enable the expansion of our Phase 1/2 PIONEER-ALS clinical trial of our first-in-class Medicine in Amyotrophic Lateral Sclerosis (ALS) into the UK and Europe. The PIONEER-ALS trial has already treated its first participant in the US and enrollment is actively underway. For more information about the trial, please see our press release: https://lnkd.in/eiSYsFTK or visit clinicaltrials.gov: https://shorturl.at/7xrir.   VectorY: dedicated to changing the trajectory of neurodegenerative diseases.   #VectorY #ALS #ALSResearch #ALSCommunity #ClinicalTrials #NeurodegenerativeDisease #VectorizedAntibodies